Bienaime Jean Jacques's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Apr 12, 2023
- Accession no.
- 0001209191-23-024073
- Filed
- Apr 12, 2023
- Trade date
- Apr 10, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $995.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bienaime Jean JacquesCIK 0001221590 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 10, 2023 | Common Stock | MOption exerciseAcquired | +10,000 | $67.81 | +$678,100 | 435,896 | Direct | |
| Apr 10, 2023 | Common Stock | SSaleDisposed | −10,000 | $99.56 | −$995,600 | 425,896 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 10, 2023 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 129,130 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.